Fluoxetine and sleep EEG: Effects of a single dose, subchronic treatment, and discontinuation in healthy subjects

Neuropsychopharmacology

Volumn 26, Issue 2, 2002, Pages 246-258

  Feige, Bernd ^a   Voderholzer, Ulrich ^a   Riemann, Dieter ^a   Dittmann, Ralf ^b   Hohagen, Fritz ^a   Berger, Mathias ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Antidepressants; EEG spectral effects; Human; Sleep; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROENCEPHALOGRAM; HALF LIFE TIME; HUMAN; HYPOTHESIS; LATENT PERIOD; MALE; NIGHT SLEEP; NONREM SLEEP; NORMAL HUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RATING SCALE; REM SLEEP; SLEEP DISORDER; SLEEP STAGE; SPECTROSCOPY;

ADULT; ALGORITHMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; FLUOXETINE; HUMANS; MALE; MODELS, PSYCHOLOGICAL; POLYSOMNOGRAPHY; SLEEP; SLEEP, REM; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0036150190     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00314-1     Document Type: Article

References (55)

1. A model of human sleep homeostasis based on EEG slow-wave activity: Quantitative comparison of data and simulations
2. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients
3. Methodological issues in pharmacokinetic-pharmacodynamic modelling
4. REM sleep in depression
5. Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: An open pilot trial in medicated and unmedicated patients
6. Sleep/waking and EEG power spectrum effects of a nonselective serotonin (5-HT) antagonist and a selective 5-HT reuptake inhibitor given alone and in combination
7. Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria
8. A comparison of psychomotor and EEG effects of desipramine, clomipramine and fluoxetine
9. Sleep homeostasis in humans and rats
10. Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression
11. Effects of prior fluoxetine treatment on EEG sleep in women with recurrent depression
12. Pharmacokinetics of the selective serotonin reuptake inhibitors
13. Estimation of the time course of slow-wave sleep over the night in depressed patients: Effects of clomipramine and clinical response
14. Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-halflife hypnotics in healthy subjects
15. Quantitative EEG analysis of a single dose of psychotropic drugs in healthy probands
16. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial
17. Newer antidepressants and the discontinuation syndrome
18. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
19. Persistent effects of antidepressants: EEG sleep studies in depressed patients during maintenance treatment
20. Clomipramine and EEG sleep in depression
21. EEG sleep changes as predictors in depression
22. Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder
23. Fluvoxamine versus desipramine: Comparative polysomnographic effects
24. Antidepressant discontinuation: A review of the literature
25. Loading dose imipramine-new approach to pharmacotherapy of melancholic depression
26. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram
27. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects
28. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine
29. Use of pattern analysis to identify true drug response. A replication
30. Identification of true drug response to antidepressants. Use of pattern analysis
31. How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay
32. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects
33. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
34. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
35. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities
36. Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses
37. Serotonin reuptake inhibitor discontinuation syndrome. A hypothetical definition
38. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers
39. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
40. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression
41. The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: Integrating psychological and biological factors
42. Delayed onset of action of antidepressants - Fact or fiction?
43. Fluoxetine, amitriptyline and the electroencephalogram
44. Effects of fluoxetine on the polysomnogram in outpatients with major depression
45. The effect of fluoxetine on sleep: A longitudinal, double-blind polysomnographic study of healthy volunteers
46. Discontinuing antidepressant treatment in major depression
47. Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs
48. Drug effects on REM sleep and on endogenous depression
49. Nefazodone and REM sleep: How do antidepressant drugs decrease REM sleep?
50. REM sleep reduction effects on depression syndromes
51. Sleep deprivation with consecutive sleep-phase advance therapy in patients with major depression: A pilot study
52. Action of trimipramine on sleep and pituitary hormone secretion
53. Quantitative pharmaco-electroencephalographic differentiation between the CNS effects of bromocriptine and imipramine, drugs with qualitatively different antidepressant properties
54. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study